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1. INTRODUCTION 
Cancer is a multi-factorial disease primarily 
characterized by uncontrolled proliferation of cells, local 
tissue invasion and their ability to metastasize. It remains 
the third leading cause of death in the world after heart 
and infectious diseases 1. 
Years of intense research and billions of dollars in 
spending have dramatically increased knowledge of the 
causes and biology of cancer, leading to the development 
of many improved treatment strategies. Yet, the 
diagnosis and treatment of many cancers still remain 
elusive and a major barrier to effective clinical outcomes, 
thereby, millions of deaths every year are still caused by 
cancer. Thus, early detection and development of even 
more effective therapies are crucial for the optimal 
management of cancer 2. 
Current cancer treatment relies on the use of surgery, 
radiotherapy and chemotherapy from which 
chemotherapy is the common approach to the chronic 
management of cancer. However, in the majority of 
cases, surgery and radiotherapy are used in combination 
with chemotherapy 3. Unfortunately, current cancer 
therapies are largely limited by inability to bypass 
biological barriers, nonspecific delivery and poor 
biodistribution of drugs, ineffectiveness against 
metastatic disease, drug resistance of cancers, and lack of 
an effective modality for treatment monitoring  4. 
Over the past two decades, nanotechnology-based 
approaches have emerged as an exciting field of cancer 
therapy with promises to overcome these challenges by 
enabling the engineered nanomedicines to navigate the 
body in very specific ways, i.e., nanotechnology 
facilitates controlled, tumor specific drug accumulation 
and release 5.  
Flurries of developments in nanoscience and 
biomedicine and the convergence of these disciplines 
have now expanded the ability to design and construct 
“multifunctional” nanoparticles, combining targeted 
therapeutic and diagnostic functions in a same entity 6. 
Therefore, theranostic nanomedicines emerge as an 
alternative to the separate administration of diagnostic 
probes and pharmacologically active molecules. The 
word “theranostics” refers to the simultaneous 
integration of diagnosis and therapy 7. 
The vision for nanotheranostics is to design nanocarriers 
which will serve a dual purpose by allowing both 
treatment and diagnosis to be contained in an „all in one‟ 
package. 
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ABSTRACT 
Despite  improvements  in  our  understanding  of cancer  and  the  emerging  concept  of personalized medicine for the 
treatment of this disease, it is still one of the leading causes of death worldwide. Although, in recent years, significant advances 
have been achieved in cancer therapy, many tumors are still challenging to treat and novel strategies are required to effectively 
combat this deadly disease. Nanotheranostics is a burgeoning field which makes use of nanotechnology for diagnosis and 
therapy of cancer. The recent advancement in the area of nanotechnology has enabled a new generation of different types of 
nanomaterials composed of either inorganic or polymer based nanoparticles to be useful for nanotheranostics applications such 
as to diagnose and treat diseases and monitoring the therapeutic response in vivo at molecular level; to enhance the control, 
evaluation and optimization of drug delivery and release; to target the drug by conjugating theranostic nanoplatformes with 
biological ligands. This review, therefore, summarizes the various nanocarriers developed so far for the simultaneous imaging 
and therapy, strategies for their targeted delivery, their potential applications and the challenges in their development and 
application for cancer therapy. 
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In fact, the nanocarriers will be designed to target a 
certain disease. A probe inserted into their design allows 
them to be tracked in the body and a drug that is carried 
together with the probe will be released if the nanocarrier 
binds to the cell, starting the therapy of the disease, 
making the treatment of the diagnosis immediate and 
saving valuable time 
8
. Hence, in this review, the various 
nanocarriers developed so far for the simultaneous 
imaging and therapy, the formulation and strategies by 
which these nanotheranostics are delivered to the target 
site, the application of nanotheranostics and challenges 
in using nanotheranostics for cancer therapy are 
discussed. 
2. NANOTHERANOSTIC AGENTS FOR CANCER 
IMAGING  
Different types of nanomaterials have been developed to 
provide contrast in medical imaging. They can be 
constructed by either organic materials (liposomes, 
polymeric micelles, dendrimers, etc), inorganic ones 
(iron oxide, gold, mesoporous silica, etc), or organic 
inorganic hybrid materials 9. Nanotheranostics can be 
classified based on the nanoplatform delivery system 
employed or by the agents coupled with drugs to provide 
imaging functions. An overview of the different types of 
nanotheranostics is discussed below with their schematic 
diagram (Figure 1)  
 
 
 
Figure 1: Schematic diagram of theranostics: A) polymer-drug conjugate; B) polymeric nanoparticle; C) solid lipid 
nanoparticle; D) dendrimer; E) liposome; F) micelle; G) gold nanoparticle; and H) carbon nanotube  9. 
2.1. Liposome and micelle based theranostics  
Liposomes  and micelles  are by far the most widely used 
and studied nanomaterials for cancer therapy. These 
lipid-based nanoparticles (LNPs) are synthesized from 
lipids containing a hydrophilic head group and lipophilic 
tail that spontaneously form spheres at critical 
concentrations 10, 11. Liposomes are spherical vesicles 
with concentric phospholipid bilayers enclosing aqueous 
compartment 12 whereas micelles or polymeric micelles 
are nanosized (typically in the range of 20–100 nm) 
spherical structures, composed of amphiphilic block 
copolymers, which self-assembles to form a core/shell 
structure in aqueous media 13.   
Currently theranostic liposomes are either being 
designed bearing non-invasive multimodal imaging 
agents like fluorescent probes, radio-isotopes and 
nanoparticle like magnetic nanoparicles or quantum dots 
(QDs). Diagnosis by theranostic liposomes have been 
reportedly done by utilizing magnetic resonance imaging 
(MRI), positron emission tomography (PET) imaging, 
single-photon emission computed tomography (SPECT) 
and near infrared resonance (NIR) fluorescent imaging 
14. 
The imaging agents can be entrapped within the 
hydrophobic core or linked covalently to the surface of 
the liposomes and the therapeutic agent can be either 
encapsulated in the lipophilic core or embedded in the 
lipophilic bilayer shell. The liposomes can then be 
further conjugated with molecular probe for targeting. 
Such multi-functional liposomes may circulate for 
prolonged periods in the blood, evading host defenses, 
and gradually release drug by targeting and 
simultaneously facilitate in vitro or in vivo imaging 7. For 
instance, Shihong Li and his co-workers synthesized 
liposomal nanotheranostic of doxorubicin by preparing 
Gadolinium-based liposomes composed and found a 
promising result 15. 
Similarly, micelles are emerging as powerful, 
multifunctional nanotherapeutic platforms for cancer 
imaging and therapeutic applications and as theranostic 
delivery systems in cancer management 11. Sailor and 
park 16 have established a multifunctional micellar 
platform that incorporates a targeting ligand, pH-
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stimulated release of doxorubicin (DOX), and an MRI-
visible agent. In this design, DOX and a cluster of 
superparamagnetic iron oxide nanoparticles (SPIO) 
nanoparticles (8 nm in diameter) were loaded into the 
cores of polyethyleneglycol-polylacticacid (PEG-PLA) 
micelles, while a cRGD ligand on the micelle surface 
(cRGD-DOX-SPIO micelles) was used for targeting. The 
resulting targeted, multifunctional micelles, measuring 
45-48 nm in diameter, showed increased uptake in vitro 
in avb3-over expressing endothelial tumor cells. 
2.2. Polymer and dendrimer based theranostics 
Polymeric nanomaterials have been extensively studied 
for their biocompatibility, versatility and multi-
functionality and offer a suitable platform for tumor 
imaging and therapy because of their well-defined and 
controllable physiochemical properties, size, and 
degradation rate, their surface “upgradability” (meaning 
their surfaces can be easily modified with various 
targeting ligands) and their ability to carry various types 
of therapeutic agents and/or imaging probes (Figure 2) 
17
. 
So far, a number of polymeric platforms have been 
applied in cancer therapy to enhance anticancer agents‟ 
efficacy, prolong drug circulation half-life, and provide 
stimuli-responsive drug release and targeting delivery. 
Some of these polymer-based nanocarriers are currently 
under various stages of clinical development 18. 
 
 
Figure 2: The three main components that a polymer conjugate combines for theranostics18 
 
Sailor and Park 16 has synthesized multifunctional 
polymer system co-encapsulated with a hydrophobic 
therapeutic agent (doxorubicin) and either hydrophobic 
superparamagnetic nanocrystals or hydrophobic quantum 
dots, using an oil-in-water emulsion and a subsequent 
solvent evaporation technique and a folate group was 
coupled onto the surface of the polymeric hybrid 
nanoparticles to target cancer cells‟ folate receptor. The 
prepared polymeric hybrid nanoparticles had uniform 
shapes and well targeted as it was evidenced by optical 
(quantum dots) and MR (magnetic nanocrystals) imaging 
techniques 1. In another study done by loading poly 
(HPMA) based theranostic copolymers with Cu-64 
which acts as intrinsic theranostic agent and cRGD as 
targeting ligand for targeting tumor angiogenesis, The 
PET showed higher accumulation of Poly(HPMA)-
c(RGD)-
64
Cu in tumor sites after IV injection than the 
non targeted Poly(HPMA)-
 64
Cu conjugate 19. 
Like polymer nano particles, dendrimer-based NPs have 
also been employed as nanotheranostic agents because of 
their unique characteristics which a single dendrimer can 
act as a platform for imaging and targeting agents to 
identify cancer cells 20, 21. Taking these unique 
characteristics as an advantage different studies has been 
done 22, 23. Among these, Zhang and his group 22 have 
synthesized an ethylenediamine core poly (amido amine) 
(PAMAM) generation five dendrimer which has a 
diameter of about 5 nm and more than 100 functional 
primary amines on the surface that has the potential to be 
used for targeting, imaging, and intracellular drug 
delivery, by covalently attaching to folic acid, 
fluorescein, and methotrexate in proper ratio. This 
multifaceted theranostic preparation, showed 100-fold 
higher cytotoxicity than free methotrexate.  
2.3. Noble metal based theranostics 
Noble metals like gold, silver, and/or platinum have been 
extensively studied as theranostics due to their unique 
and distinctive characteristics such as high surface-to-
volume ratio, broad optical properties, ease of synthesis, 
and facile surface chemistry and functionalization 24. 
Noble metal NPs present optical properties, which can be 
easily tuned to desirable wavelengths according to their 
shape, and composition enabling their imaging and 
photothermal applications under native tissue. These NPs 
can also be easily functionalized with various moieties, 
such as antibodies, peptides, and/or DNA/RNA to 
specifically target different cells and with biocompatible 
polymers. Moreover, they can efficiently convert light or 
radio frequencies into heat, thus enabling thermal 
ablation of targeted cancer cells 25. 
2.3.1. Gold-based theranostics 
Due to their potential to facilitate both the diagnosis and 
treatment of cancer through their advantageous chemical 
and physical properties like superior biocompatibility 
and well-established strategies for surface modification 
(i.e. gold-thiol bonding), gold-based nanomaterials have 
been investigated as theranostic nanoplatforms 26.  One 
of the most attractive attributes of gold nanomaterials 
(GNMs) is the tunable optical property that mediates the 
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localized surface plasmon resonance (LSPR). The LSPR 
of gold nanomaterials can be adjusted by tuning their 
morphology; gold (Au) NP, nanorod (AuNR), nanoshell, 
and nanocage exhibit distinctive optical and thermal 
properties, which can readily upgrade gold nanomaterials 
to be prospective theranostic agents 27. Wang and his 
coworkers 
9
  have developed leyered double hydroxide-
gadolinium/gold (LDH-Gd/Au) nanocomposite platform 
for CT/MRI dual-modality imaging and anti-cancer drug 
delivery. The LDH-Gd/Au nanocomposite showed high 
non-anionic anti-cancer drug DOX loading capacity (264 
mg drug/g carrier), and the loaded DOX shows an 
interesting pH-responsive release feature, which is 
favorable for avoiding quick drug release in the neutral 
blood system but promoting drug release at acidic tumor 
sites or within cells. Despite their property is fascinating 
to tune as theranostics, GNMs have their own intrinsic 
disadvantages like high cost of production and an issue 
of stability in physiological conditions. For clinical 
translation of GNMs, more stable surface chemistry is 
greatly required. 
2.3.2. Silver based theranostics 
The cytotoxicity of silver nanoparticles (Ag NPs) to 
various cell lines is effectuated by conjugating with 
various chemicals, biomolecules, and anticancer drugs 
via covalent or non-covalent bonds. For instance, 
Mukherjee and his coworker 29 have developed bio-
synthesized silver based nanoparticles (b-AgNps) from 
reduction of silver nitrate (AgNO3). The formed 
nanoparticle exhibited multifunctional characteristics for 
targeted drug delivery and fluorescence imaging of cells 
that could be utilized to detect the localization of drug 
molecules inside the cancer. Thus, there is a strong hope 
in b-AgNps for their use as theranostic agents in cancer 
diagnosis and therapy 28. However, the only limitation 
that withholds Ag Nps from extensive application in 
cancer therapy and diagnosis is its poor biocompatibility 
to the in vivo system. One recent works in this regard 
suggested that the aforementioned problem can be 
overcome by capping Ag Nps with stem latex from a 
medicinal plant, Euphorbia nivulia. The modified NPs 
are found to be biocompatible and cytotoxic against 
human lung carcinoma cells (A549) in a dose-dependent 
manner 17. 
2.4. Quantum dots (QDs) or Semiconductor based 
theranostics 
Quantum dots (QDs), which are small 2-10 nm light-
emitting nanocrystals made from semiconductor 
materials typically from selenides or sulfides of cadmium 
or zinc, are becoming an important class of biomaterials, 
because they possess unique optical and electronic 
properties depending on their size and composition. To 
improve QD solubility, sensitivity, specificity, and 
visualization in the target tissue, the surface of QD can 
be modified by ligand exchange with simple thiol-
containing molecules, dendrons, peptides, and 
encapsulation by a layer of amphiphilic copolymers. This 
strategy not only helps to facilitate solubilization, but 
also provides a linker for bioconjugation of peptides, 
antibodies, oligonucleotides, or small molecule drugs, 
thereby multi-functionalizing the QDs for tumor 
targeting, tumor imaging and drug delivery 29. 
QD based theranostic agents can be prepared by loading 
QDs via physical adsorption such as methotrexate 
(MTX) loaded QDs or co-encapsulation of QDs and drug 
into lipid micelles 30. Following the above method of 
preparation  Liu et al have successfully prepared multi-
functional QD in which a targeting ligand (RNA 
aptamers covalently attached to the surface of QD, which 
also serve as a drug carrier vehicle) and doxorubicin are 
incorporated as a therapeutic agent and a drug, 
respectively 31. 
2.5. Carbon nanotubes and fullerenes 
Carbon nanotubes (CNTs) are cylindrical tubes 
composed solely of carbon and can either be formed as 
single-walled (consists of a single graphene cylinder) 
with a diameter of 0.8 - 2 nm or multi-walled (comprises 
several concentric graphene cylinders) with a diameter of 
5-20 nm. Different nanocarbons such as carbon 
nanotubes, graphene, fullerene, nanodiamond and carbon 
nanoparticles (CNPs) (Figure 3) have been developed as 
delivery vehicles for imaging and therapeutic agents 32. 
 
 
Figure 3: Different types of nano-carbons explored for theranostic applications 32 . 
Their interesting physico-chemical features such as high 
surface area, ultra-light weight, pseudoaromatic 
structure, tunable surface chemistry, ease of drug 
loading, fluorescence detectability and photoacoustic 
effects make them a potential asset in the arsenal of 
theranostic nanocarriers. Recent expansion of surface 
engineering and bioconjugation techniques has 
accelerated the growth of multi-functional CNT-based 
platforms, concomitantly combined with multiple 
diagnostic and therapeutic entities. Such multifunctional 
yet „chemically partitioned‟ CNTs can easily penetrate 
biological barriers like a „nanoneedle‟ facilitating the 
internalization of various cargos inside the cells that 
would not otherwise be taken up 5. A promising result 
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has been found in a study done by encapsulating 
Doxorubicin as chemotherapeutic agent and gadolinium-
based contrast agents for MRI imaging within the lipid 
bilayer of fullerene liposomes to target interleukin (IL-
13) receptors in brain cancer therapy. After verifying the 
selective binding of fullerene liposome based 
theranostics to the IL-13 receptor, its antitumor effect 
was tested in mice bearing brain tumors and better 
shrinkage of the tumor was observed 33. 
2.6. Magnetic nanoparticles based theranostics 
Magnetic NP-based theranostics, along with their 
magnetic property as nanostructured contrast probes for 
MRI, are beneficial due to their biocompatibility, cost-
effectiveness and their large surface area to volume ratio 
that enables loading of a wide range of functionalities, 
such as targeting, imaging and therapeutic features, onto 
their surfaces. Among the magnetic NPs, 
superparamagnetic iron oxide nanoparticles (SPIONPs), 
mainly magnetite and maghemite, are the most 
commonly used nanomaterials 34. 
The main drawback of magnetic nanparticles is their 
poor water solubility and intracellular aggregation. In 
order to confer colloidal suspendability to the particles, 
hydrophilic polymers are added to passivate the 
nanocrystal surface that would typically protect particles 
from aggregation. For instance, Santra and his coworkers 
utilized poly (acryl amide) (PAA) to coencapsulate a 
lipophilic NIR dye and the anticancer drug taxol within 
hydrophobic pockets, resulting in a theranostic 
nanocarrier for dual fluorescence and MR-based imaging 
and monitoring of drug delivery. Foliate; furthermore, 
was conjugated onto PAA-IONPs, yielding targeting 
functionality aimed at the targeted killing of foliate 
receptor-overexpressing cancer cells, demonstrated by 
optical/MR imaging. In addition, their work pointed out 
that incorporating polymer could somehow alleviate the 
poor water solubility problem of magnetic nanoparticles 
35.    
2.7. Silica based nanotheranostics  
The properties of many nanomaterials are dependent on 
their size as it approaches the nanosize range and the 
percentage of atoms present on their surfaces, but silica-
based nanoparticles (SiNPs) have constant physical 
properties similar to those of bulk materials, except that 
the total surface area increases as the size decreases. 
Indeed, what really makes SiO2 NPs predominate in 
nanobiomedicine is the higher surface area, their well-
defined tunable nanostructures and well-established 
siloxane chemistry, which allow successful fabrication of 
the desired surface for diagnostic and therapeutic 
requests 26. There are two types of silica nanoparticles, 
solid silica nanoparticles and mesoporous silica 
nanoparticles. Methods such as sol-gel synthesis and 
microemulsion have been employed to prepare silica 
based nanoparticles for diagnostic imaging and 
therapeutic applications 36. A wide variety of imaging, 
targeting ligands and therapeutic agents, such as 
superparamagnetic iron oxide nanoparticles, and Gd 
complexes for MRI imaging, quantum dots, genes, 
chemotherapeutic drugs like Doxorubicin, Captothecin, 
Paclitaxel, have been loaded/grafted/encapsulated into 
mesoporous silica based nanotheranosticss which are 
expected to satisfy the clinical requirements following 
the systematic investigation of their biological effects 
and bio-safety, and finally find their applications in 
clinical practices to benefit human beings 37. Chen and 
his coworker 5 reported development of trifunctionalized 
MSNs for theranostic application that combined imaging, 
targeting, and therapeutic agent in one single-particle 
platform. This theranostic platform exhibited excellent 
targeting of human glioblastoma cells and minimal 
collateral damage, but highly potent therapeutic effects. 
3. TRIGGERED NANOTHERANOSTIC 
DELIVERY 
Obviously, both passive and active targeting mechanisms 
can be used to target nanotheranostics to specific 
cancerous cell. In addition to passive accumulation and 
active tumor-specific targeting strategies, another 
important approach for tumor-localized drug release is to 
design „smart‟ nanotheranostics, which, can respond to 
an extrinsic stimulus (e.g. Temperature, magnetic field, 
ultrasound, and light) or an intrinsic trigger (e.g. pH, 
glucose, redox potential, and lysosomal enzymes) which 
is specific to the disease environment 38.  
3.1. Temperature responsive nanotheranostics 
Temperature responsive liposomal (TSL) formulations 
hold great promise to further increase the drug 
concentration and its bioavailability in the tumor. 
However, the need for monitoring the drug release 
process has led to the development of MRI encapsulated 
TSLs, which allows drug delivery under imaging 
guidance. When drug and a contrast agent (CA) release 
occurs simultaneously, the observed MRI contrast 
change can be used for quantification of the drug release 
39. TSLs release drugs encapsulated in the liposome 
lumen at the melting phase transition temperature (Tm) 
of the bilayer. At Tm, the lipid membrane undergoes a 
gel to a liquid-crystalline phase transition because of 
structural changes in the liposomal membrane. This is 
accompanied by transient membrane defects, which 
facilitate the rapid release of liposomal contents 40. 
3.2. PH responsive nanotheranostics 
The pH of cancer cells is lower than that of normal cells 
as a result of increased lactic acid production. The acid is 
also released to extracellular regions lowering the pH to 
bellow 7.4. This characteristic of cancer cells allows for 
pH responsive nanocarriers containing both imaging and 
therapeutic agents to specifically deliver into cancer cells 
and release their contents. LDH-Gd/Au nanocomposite 
platform has synthesized for CT/MRI dual-modality 
imaging and anti-cancer drug delivery. The LDH-Gd/Au 
nanocomposite shows high non-anionic anti-cancer drug 
DOX loading capacity (264 mg drug/g carrier), and the 
loaded DOX shows an interesting pH-responsive release 
feature, which is favorable for avoiding quick drug 
release in the neutral blood system but promoting drug 
release at acidic tumor sites or within cells 9.  
3.3. Magnetic field responsive nanotheranostics  
Magnetic nanoparticles have the capability to produce 
heat under externally applied magnetic field. While the 
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term “Hyperthermia” in the literature, so far has been 
confined only to include the use of heat for therapy, it 
was found from the recent literature studies that MNP-
based hyperthermia could also be utilized to generate 
intense local heating within polymeric matrices thereby 
creating voids for the release of encapsulated drugs. One 
example of an activable drug-delivery system by a 
magnetic field used dextran-coated IONPs with MRI 
capability and conjugated fluorescein-labeled 18 base-
pair oligonucleotide duplexes to the particle. Upon 
electromagnetic field activation, the duplex structure of 
the fluorescein-labeled oligonucleotides melted and 
released the fluorescein, which served as the model drug, 
into the tumor model 41. 
4. APPLICATIONS OF NANOTHERANOSTICS IN 
CANCER THERAPY 
Before initiating treatment of various diseases, primarily 
cancer, it is essential to carry out diagnostic imaging to 
understand the cellular phenotype(s) and heterogeneity 
of the tumor. The ultimate goal of the theranostic field is 
to gain the ability to image and monitor the diseased 
tissue, delivery kinetics, and drug efficacy. Here below 
the applications of nanotheranostics in the treatment of 
various types of cancers are presented. 
4.1. Solid Tumors 
A solid tumor consists of an abnormal mass of cells 
which may stem from different tissue types such as liver, 
colon, breast, or lung, and which initially grows in the 
organ of its cellular origin. When these tumors reach a 
critical size, diffusion of chemotherapeutic agents into 
the tumor becomes impaired. Thus new strategies that 
overcome this problem should be designed. Owing to 
their small size, nanotheranostics, especially those 
conjugated with targeting ligands have the ability to 
deliver the therapeutic agent deep into the tumor tissue 
thereby enhancing the accumulation of drugs within the 
tumor. Imaging agents encapsulated with the 
chemotherapeutic agents will provide real time 
visualization of target as well as off target site 
accumulation of chemotherapeutic agents helping 
immediate assessment of over/under treatment conditions 
42. 
4.2. Metastases 
Metastasis is the development of secondary malignant 
growths at distant sites as a result of the spread of cancer 
from a primary tumor site. It occurs through the process 
of spreading cancers into neighboring normal tissues, 
intravasation in to the blood stream or lymphatic‟s, 
extravasation from the blood stream into different tissues 
of the body and the formation of a metastasized tumor. 
Metastases primarily develop during the late stages of 
cancer and accounts for greater than 90% of all cancer 
related deaths 43. Various treatment strategies have been 
designed for the treatment of metastasized cancers, but 
due to the complexity of tumor progression, tumor 
composition, and drug resistance mechanisms these are 
unable to improve the prognosis apart from improving 
survival. Thus nanotheranostics are believed to overcome 
this problem by early detection of tumors and inhibiting 
cell invasion by the interaction of specifically engineered 
nanomaterials with cell surface proteins involved in cell 
invasion. They also enable the researchers to visualize 
and analyze the distribution of drugs to all metastasized 
cancer cells and to monitor treatment efficacy 44. 
4.3. Multidrug resistance 
Drug resistance, which allows tumors to evade 
chemotherapeutic agents, has emerged as a major 
obstacle that limits the efficacy of chemotherapy 45. This 
mechanism for tumor survival under chemotherapeutic 
treatment is known as multidrug resistance (MDR). P-
glycoprotein (P-gp), an efflux transporter, which is 
overexpressed on the plasma membrane of cancer cells, 
is thought to be responsible for MDR 46. 
Different mechanisms can be employed for uptake of 
theranostic nanomedicines into the tumor. Irrespective of 
the exact mode of cellular entry, endocytosed 
nanomedicines eventually end up in lysosomes, and thus 
are carried relatively deep into cells, far beyond the reach 
of trans-membrane localized drug efflux pumps. In 
theory, this strategy, therefore ensures efficient delivery 
of chemotherapeutic agents into the cytoplasm of cells, 
without being sensed and removed by MDR proteins as 
opposed to free (i.e. non-nanomedicine-associated) 
chemotherapeutic drugs, which upon passive diffusion 
across the cellular membrane are rapidly sensed and 
effluxed by MDR proteins 47. 
4.4. Hematological cancers 
Hematologic cancer is a cancer that affects the body‟s 
blood, bone marrow
 
or lymphatic system.
 
As compared 
to solid tumors, these cancers inflict greatest challenge 
for therapy. The tumor microenvironment of these 
cancers is extremely diverse than with solid tumors and 
offers growth factors for cancer cells growth and survival 
resulting in de novo drug resistance. Likewise, treated 
cancer cells can lyse and release their components 
directly into the blood, which leads to potentially lethal 
electrolyte and metabolic disturbances. Therefore, 
theranostic nanoparticles aim to induce apoptosis 
through the formation of free radicals, so that cellular 
components will be packaged into apoptotic bodies for 
macrophage uptake rather than directly released into the 
circulation, and to visualize this phenomenon 12 . 
4.5. Cancer stem cells (CSCs) 
Tumors, like normal adult tissues, contain stem cells that 
both self renew and give rise to differentiated progeny. 
They are the only cells that can maintain tumor growth 
indefinitely. The self-renewal properties of the CSCs are 
thus the real driving force behind tumor growth. The 
identification of markers that allow the prospective 
isolation of CSCs from whole tumor tissues helps to 
develop an understanding of several important biological 
properties of CSCs such as cell origin for a given tumor, 
signaling pathways for self-renewal and/or 
differentiation of CSCs, the molecules uniquely 
expressed on CSCs, and the mechanisms by which CSCs 
escape conventional therapies. Studies on these 
biological properties should lead to the development of 
therapies that target the CSC population and eliminate 
the „engine‟ that drives tumors to grow, invade, and seed 
metastatic lesions 48. Along with the tremendous advance 
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in the discovery of various cell surface markers 
distinguishing CSCs from non-CSCs, NPs are expected 
to direct theranostics to CSCs and improve the CSC-
specific therapies. Taking the stem cell marker CD133, 
for example, it was found to be expressed on the surfaces 
of stem cells of brain cancer, breast cancer, prostate 
cancer, lung cancer, colon cancer, pancreatic cancer, 
ovarian cancer, and liver cancer 18. 
5. CHALLENGES OF NANOTHERANOSTICS  
Theranostic nanoplatforms with their unique capability 
for simultaneous imaging and treatment are the hopes of 
effective cancer therapy. However, before translation of 
nanotheranostics to their clinical application, there are a 
number of forbidding challenges that confront the 
developers of theranostic nanoplatforms. These 
challenges are diverse and they are all in part difficult 
due to the lack of physiologically relevant test-beds 
available to designers. It is critical that the engineering of 
these nanoplatforms be guided by biological 
considerations if they are to be translated into clinical 
use. The biological issues are complex and can only be 
duplicated by an in vivo system 49. To date majority of 
theranostic nanomedicines are tested in vitro and 
relatively few have been investigated for in vivo efficacy 
27. This may be attributed to lack of access to the relevant 
animal models or robust collaborations with other 
experts in the field. This may lead sluggish dissemination 
of facts to the larger nanomedicine community, which 
further influences future step-by-step processing of 
nanotheranostics. 
6. CONCLUSION AND PROSPECTIVE 
Actually theranostics is representative of the evolution of 
multidisciplinary nanoscience, as a routine meeting of 
multiple disciplines including chemistry, material 
science, Electromagnetics, biology, medical physics, and 
oncology. Nanotheranostics will be developed in a 
broader sense so that therapy and diagnostics can work 
hand in hand. It is possible to predict high-impact 
advances in this field as researchers‟ pioneer approaches 
to develop nanoscale platforms with multiple 
functionalities 50. It is likely that in the coming years, 
TNPs will emerge and enter clinical trials. Nanoparticles 
that can simultaneously detect, image, and treat disease 
may one day become the norm rather than the exception 
51.  
Further advancement of nanotheranostics by using 
multiple imaging agents to overcome the limitations of 
single imaging agent and combination of drugs to 
achieve better therapeutic efficacy is believed to be 
developed in the future with reliable and reproducible 
synthetic procedures and to be scaled up to production 
levels without much difficulty 52. 
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